{"id":"NCT00708682","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico","officialTitle":"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2008-07-02","resultsPosted":"2011-02-25","lastUpdate":"2011-10-25"},"enrollment":225,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Vaccines, Pneumococcal"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"}],"summary":"The purpose of this study will be to evaluate safety, tolerability and immunogenicity of 13-valent pneumococcal vaccine in healthy infants given with routine pediatric vaccinations in Mexico.","primaryOutcome":{"measure":"Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (â‰¥) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series","timeFrame":"1 month after the infant series (7 months of age)","effectByArm":[{"arm":"13vPnC","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":9,"countries":["Mexico"]},"refs":{"pmids":["23965217"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":223},"commonTop":["Irritability","Tenderness (any)","Tenderness (any)","Irritability","Decreased appetite"]}}